Malcolm A. Smith

34.5k total citations · 4 hit papers
292 papers, 12.7k citations indexed

About

Malcolm A. Smith is a scholar working on Molecular Biology, Oncology and Neurology. According to data from OpenAlex, Malcolm A. Smith has authored 292 papers receiving a total of 12.7k indexed citations (citations by other indexed papers that have themselves been cited), including 125 papers in Molecular Biology, 78 papers in Oncology and 75 papers in Neurology. Recurrent topics in Malcolm A. Smith's work include Neuroblastoma Research and Treatments (72 papers), Acute Lymphoblastic Leukemia research (58 papers) and Cancer therapeutics and mechanisms (29 papers). Malcolm A. Smith is often cited by papers focused on Neuroblastoma Research and Treatments (72 papers), Acute Lymphoblastic Leukemia research (58 papers) and Cancer therapeutics and mechanisms (29 papers). Malcolm A. Smith collaborates with scholars based in United States, Australia and United Kingdom. Malcolm A. Smith's co-authors include Peter J. Houghton, John M. Maris, C. Patrick Reynolds, Richard B. Lock, E. Anders Kolb, Richard Görlick, Gregory H. Reaman, Stephen T. Keir, Christopher L. Morton and Hernán Carol and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Nature reviews. Cancer.

In The Last Decade

Malcolm A. Smith

280 papers receiving 12.4k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma

2010 1.2k citations Malcolm A. Smith, Robert C. Seeger et al. profile →
Outcomes for Children and Adolescents With Cancer: Challenges for the Twenty-First Century

2010 744 citations Malcolm A. Smith, Gregory H. Reaman et al. profile →
Study design and cohort characteristics of the childhood cancer survivor study: A multi‐institutional collaborative project

2002 553 citations Malcolm A. Smith et al. profile →
Declining childhood and adolescent cancer mortality

2014 363 citations Malcolm A. Smith, Gregory H. Reaman et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Malcolm A. Smith	4.9k	3.3k	3.0k	2.8k	2.2k	292	12.7k
Richard Sposto	3.3k 0.7×	3.4k 1.0×	3.9k 1.3×	2.5k 0.9×	1.8k 0.8×	282	13.4k
Gregory H. Reaman	4.2k 0.9×	3.6k 1.1×	2.7k 0.9×	6.3k 2.2×	4.9k 2.2×	306	15.8k
Lisa Diller	2.9k 0.6×	3.3k 1.0×	3.2k 1.1×	2.4k 0.8×	3.4k 1.5×	220	10.8k
Joseph L. Wiemels	4.9k 1.0×	1.4k 0.4×	1.2k 0.4×	3.0k 1.0×	2.0k 0.9×	256	11.8k
Huib N. Caron	6.3k 1.3×	2.5k 0.7×	3.1k 1.0×	1.4k 0.5×	2.6k 1.2×	151	12.4k
James M. Boyett	4.4k 0.9×	2.2k 0.7×	4.2k 1.4×	3.5k 1.2×	2.8k 1.3×	232	15.2k
Reiner Siebert	6.2k 1.3×	6.8k 2.0×	2.6k 0.9×	1.1k 0.4×	854 0.4×	332	20.1k
R.J. Arceci	5.1k 1.0×	3.5k 1.1×	592 0.2×	2.2k 0.8×	1.3k 0.6×	390	12.5k
John J. Mulvihill	2.7k 0.5×	2.8k 0.8×	1.3k 0.4×	2.4k 0.9×	2.8k 1.3×	249	12.7k
Wendy B. London	7.1k 1.4×	3.9k 1.2×	12.0k 4.0×	905 0.3×	1.6k 0.7×	276	17.4k

Countries citing papers authored by Malcolm A. Smith

Since Specialization

Citations

This map shows the geographic impact of Malcolm A. Smith's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Malcolm A. Smith with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Malcolm A. Smith more than expected).

Fields of papers citing papers by Malcolm A. Smith

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Malcolm A. Smith. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Malcolm A. Smith. The network helps show where Malcolm A. Smith may publish in the future.

Co-authorship network of co-authors of Malcolm A. Smith

This figure shows the co-authorship network connecting the top 25 collaborators of Malcolm A. Smith. A scholar is included among the top collaborators of Malcolm A. Smith based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Malcolm A. Smith. Malcolm A. Smith is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Krytska, Kateryna, Jennifer Pogoriler, Daniel Martínez, et al.. (2022). Evaluation of the DLL3-targeting Antibody–Drug Conjugate Rovalpituzumab Tesirine in Preclinical Models of Neuroblastoma. Cancer Research Communications. 2(7). 616–623. 5 indexed citations

Robles, Andrew J., Raushan T. Kurmasheva, Abhik Bandyopadhyay, et al.. (2020). Evaluation of Eribulin Combined with Irinotecan for Treatment of Pediatric Cancer Xenografts. Clinical Cancer Research. 26(12). 3012–3023. 11 indexed citations

Hingorani, Pooja, Michael Roth, Wendong Zhang, et al.. (2020). ABBV-085, Antibody–Drug Conjugate Targeting LRRC15, Is Effective in Osteosarcoma: A Report by the Pediatric Preclinical Testing Consortium. Molecular Cancer Therapeutics. 20(3). 535–540. 23 indexed citations

Mossé, Yaël P., Elizabeth Fox, David T. Teachey, et al.. (2019). A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921). Clinical Cancer Research. 25(11). 3229–3238. 79 indexed citations

Richmond, Jennifer, Kathryn Evans, Hernán Carol, et al.. (2017). Bioluminescence Imaging Enhances Analysis of Drug Responses in a Patient-Derived Xenograft Model of Pediatric ALL. Clinical Cancer Research. 23(14). 3744–3755. 17 indexed citations

Murphy, Brendan, John M. Maris, E. Anders Kolb, et al.. (2016). Evaluation of Alternative In Vivo Drug Screening Methodology: A Single Mouse Analysis. Cancer Research. 76(19). 5798–5809. 40 indexed citations

Farrar, Jason E., Rhonda E. Ries, Daniel Wai, et al.. (2016). Genomic Profiling of Pediatric Acute Myeloid Leukemia Reveals a Changing Mutational Landscape from Disease Diagnosis to Relapse. Cancer Research. 76(8). 2197–2205. 104 indexed citations

Dolai, Sibasish, Alissa K. Robbins, Ling Zhong, et al.. (2016). Quantitative Phosphotyrosine Profiling of Patient-Derived Xenografts Identifies Therapeutic Targets in Pediatric Leukemia. Cancer Research. 76(9). 2766–2777. 12 indexed citations

Osgood, Christy, Susan M. Kitchen-Goosen, Girma M. Woldemichael, et al.. (2016). Identification of Mithramycin Analogues with Improved Targeting of the EWS-FLI1 Transcription Factor. Clinical Cancer Research. 22(16). 4105–4118. 57 indexed citations

10.

Khaw, Seong Lin, Santi Suryani, Kathryn Evans, et al.. (2016). Venetoclax responses of pediatric ALL xenografts reveal sensitivity of MLL-rearranged leukemia. Blood. 128(10). 1382–1395. 112 indexed citations

11.

Richmond, Jennifer, Hernán Carol, Kathryn Evans, et al.. (2015). Effective Targeting of the P53–MDM2 Axis in Preclinical Models of Infant MLL -Rearranged Acute Lymphoblastic Leukemia. Clinical Cancer Research. 21(6). 1395–1405. 41 indexed citations

12.

Forest, Amélie, Dale L. Ludwig, Ying Wang, et al.. (2015). Intrinsic Resistance to Cixutumumab Is Conferred by Distinct Isoforms of the Insulin Receptor. Molecular Cancer Research. 13(12). 1615–1626. 27 indexed citations

13.

Suryani, Santi, Richard C. Harvey, Hernán Carol, et al.. (2014). Evaluation of the In Vitro and In Vivo Efficacy of the JAK Inhibitor AZD1480 against JAK-Mutated Acute Lymphoblastic Leukemia. Molecular Cancer Therapeutics. 14(2). 364–374. 43 indexed citations

14.

Smith, Malcolm A., C. Patrick Reynolds, Min H. Kang, et al.. (2014). Synergistic Activity of PARP Inhibition by Talazoparib (BMN 673) with Temozolomide in Pediatric Cancer Models in the Pediatric Preclinical Testing Program. Clinical Cancer Research. 21(4). 819–832. 90 indexed citations

15.

Carol, Hernán, Barbara Szymanska, Kathryn Evans, et al.. (2013). The Anti-CD19 Antibody–Drug Conjugate SAR3419 Prevents Hematolymphoid Relapse Postinduction Therapy in Preclinical Models of Pediatric Acute Lymphoblastic Leukemia. Clinical Cancer Research. 19(7). 1795–1805. 57 indexed citations

16.

Houghton, Peter J., Christopher L. Morton, Richard Görlick, et al.. (2010). Stage 2 Combination Testing of Rapamycin with Cytotoxic Agents by the Pediatric Preclinical Testing Program. Molecular Cancer Therapeutics. 9(1). 101–112. 79 indexed citations

17.

Harvey, Richard C., Charles G. Mullighan, I‐Ming Chen, et al.. (2010). Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood. 115(26). 5312–5321. 395 indexed citations

18.

Wei, Jun S., Peter A. Johansson, Qingrong Chen, et al.. (2009). microRNA Profiling Identifies Cancer-Specific and Prognostic Signatures in Pediatric Malignancies. Clinical Cancer Research. 15(17). 5560–5568. 44 indexed citations

19.

Neale, Geoffrey, Xiaoping Su, Christopher L. Morton, et al.. (2008). Molecular Characterization of the Pediatric Preclinical Testing Panel. Clinical Cancer Research. 14(14). 4572–4583. 95 indexed citations

20.

Whiteford, Craig C., Sven Bilke, Braden T. Greer, et al.. (2007). Credentialing Preclinical Pediatric Xenograft Models Using Gene Expression and Tissue Microarray Analysis. Cancer Research. 67(1). 32–40. 91 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact